Idenix takes to Europe with its Gilead patent spat

Idenix Pharmaceuticals ($IDIX) believes Gilead Sciences ($GILD) violated its patents with the blockbuster-selling hepatitis C pill Sovaldi, and the biotech has expanded its legal fight into Europe, angling for a cut of sales. In lawsuits filed in France, Germany and the U.K., Idenix claims Gilead stepped on its intellectual property related to nucleoside treatments for hep C, following a similar legal effort launched in the U.S. in December. More